Literature DB >> 28359519

Pulmonary Hypertension in Heart Failure: Pathophysiology, Pathobiology, and Emerging Clinical Perspectives.

Marco Guazzi1, Robert Naeije2.   

Abstract

Pulmonary hypertension is a common hemodynamic complication of heart failure. Interest in left-sided pulmonary hypertension has increased remarkably in recent years because its development and consequences for the right heart are now seen as mainstay abnormalities that begin in the early stages of the disease and bear unfavorable prognostic insights. However, some knowledge gaps limit our ability to influence this complex condition. Accordingly, attention is now focused on: 1) establishing a definitive consensus for a hemodynamic definition, perhaps incorporating exercise and fluid challenge; 2) implementing the limited data available on the pathobiology of lung capillaries and small arteries; 3) developing standard methods for assessing right ventricular function and, hopefully, its coupling to pulmonary circulation; and 4) searching for effective therapies that may benefit lung vessels and the remodeled right ventricle. The authors review the pathophysiology, pathobiology, and emerging clinical perspectives on pulmonary hypertension across the broad spectrum of heart failure stages.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac output; pulmonary circulation; pulmonary wedge pressure; right ventricle

Mesh:

Year:  2017        PMID: 28359519     DOI: 10.1016/j.jacc.2017.01.051

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  63 in total

1.  Prognostic significance of red cell distribution width and its relation to increased pulmonary pressure and inflammation in acute heart failure.

Authors:  Ryszard Targoński; Janusz Sadowski; Magdalena Starek-Stelmaszczyk; Radosław Targoński; Andrzej Rynkiewicz
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

2.  The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Masaru Obokata; Katlyn E Koepp; Alexander C Egbe; Brandon Wiley; Barry A Borlaug
Journal:  Circ Res       Date:  2019-01-18       Impact factor: 17.367

3.  Right Ventricular Dysfunction and Its Contribution to Morbidity and Mortality in Left Ventricular Heart Failure.

Authors:  Amresh Raina; Talha Meeran
Journal:  Curr Heart Fail Rep       Date:  2018-04

4.  Pulmonary Hypertension Subtypes and Mortality in CKD.

Authors:  Daniel L Edmonston; Kishan S Parikh; Sudarshan Rajagopal; Linda K Shaw; Dennis Abraham; Alexander Grabner; Matthew A Sparks; Myles Wolf
Journal:  Am J Kidney Dis       Date:  2019-11-12       Impact factor: 8.860

Review 5.  Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis.

Authors:  George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 6.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

Review 7.  Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.

Authors:  Carl P Walther; Vijay Nambi; Nicola A Hanania; Sankar D Navaneethan
Journal:  Am J Kidney Dis       Date:  2020-03-19       Impact factor: 8.860

8.  Paclitaxel alleviates monocrotaline-induced pulmonary arterial hypertension via inhibition of FoxO1-mediated autophagy.

Authors:  Wei Feng; Jian Wang; Xin Yan; Cui Zhai; Wenhua Shi; Qingting Wang; Qianqian Zhang; Manxiang Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-25       Impact factor: 3.000

9.  Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.

Authors:  João Manuel Santos; Víctor Cervera-Carrascon; Riikka Havunen; Sadia Zafar; Mikko Siurala; Suvi Sorsa; Marjukka Anttila; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2018-07-13       Impact factor: 11.454

Review 10.  Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension.

Authors:  Bhavadharini Ramu; Brian A Houston; Ryan J Tedford
Journal:  Curr Heart Fail Rep       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.